Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non–Small-Cell Lung Cancer
In this cohort study of patients with advanced NSCLC treated with pembrolizumab, exposure to some classes of antibiotics, to steroids (>20 mg per day of prednisone equivalent), and to PPIs was associated with worse OS, indicating that comedications should be monitored carefully in patients with immunotherapy.
Authors
- Claudia Parisi (ORCID: https://orcid.org/0000-0002-6259-8234)
- Noémie Simon‐Tillaux (ORCID: https://orcid.org/0000-0001-7138-5364)
- Stéphanie Foulon (ORCID: https://orcid.org/0000-0002-0213-0736)
- Benjamin Besse (ORCID: https://orcid.org/0000-0001-5090-8189)
- Anas Gazzah (ORCID: https://orcid.org/0000-0002-6866-6787)
- David Planchard (ORCID: https://orcid.org/0000-0002-1565-8310)
- Maxime Frélaut (ORCID: https://orcid.org/0000-0002-0263-7094)
- Lisa Derosa (ORCID: https://orcid.org/0000-0003-0527-2964)
- Ariane Laparra (ORCID: https://orcid.org/0000-0002-8275-7044)
- Pernelle Lavaud (ORCID: https://orcid.org/0000-0002-1286-5955)
- Jordi Remón (ORCID: https://orcid.org/0000-0002-9462-875X)
- Adrien Rousseau (ORCID: https://orcid.org/0000-0001-8708-1664)
- Stefan Michiels (ORCID: https://orcid.org/0000-0002-6963-2968)
- Fabrice Barlesi
Institutions
- Inserm (FR)
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- La Ligue Contre le Cancer (FR)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-09-10
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.29225
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09